Novo Nordisk A/S Stock | NOVO B.CO | DK0060534915 | A1XA8R

Date	Novo Nordisk A/S Revenue	Novo Nordisk A/S EBIT	Novo Nordisk A/S Net Income
2029e	550.96 B DKK	0 DKK	153.28 B DKK
2028e	484.37 B DKK	228.14 B DKK	134.45 B DKK
2027e	441.1 B DKK	204.12 B DKK	121.39 B DKK
2026e	411.2 B DKK	196.99 B DKK	115.15 B DKK
2025e	354.82 B DKK	164.86 B DKK	96.98 B DKK
2024e	293.68 B DKK	133.14 B DKK	79.13 B DKK
2023	232.26 B DKK	104.7 B DKK	83.68 B DKK
2022	176.95 B DKK	75.67 B DKK	55.53 B DKK
2021	140.8 B DKK	59.36 B DKK	47.76 B DKK
2020	126.95 B DKK	54.6 B DKK	42.14 B DKK
2019	122.02 B DKK	53.68 B DKK	38.95 B DKK
2018	111.83 B DKK	47.24 B DKK	38.63 B DKK
2017	111.7 B DKK	49.28 B DKK	38.13 B DKK
2016	111.78 B DKK	48.97 B DKK	37.93 B DKK
2015	107.93 B DKK	46.96 B DKK	34.86 B DKK
2014	88.81 B DKK	35.13 B DKK	26.48 B DKK
2013	83.57 B DKK	31.64 B DKK	25.18 B DKK
2012	78.03 B DKK	29.47 B DKK	21.43 B DKK
2011	66.35 B DKK	22.37 B DKK	17.1 B DKK
2010	60.78 B DKK	18.89 B DKK	14.4 B DKK
2009	51.08 B DKK	14.93 B DKK	10.77 B DKK
2008	45.55 B DKK	12.37 B DKK	9.65 B DKK
2007	41.83 B DKK	8.94 B DKK	8.52 B DKK
2006	38.74 B DKK	9.12 B DKK	6.45 B DKK
2005	33.76 B DKK	8.09 B DKK	5.86 B DKK
2004	29.03 B DKK	6.98 B DKK	5.01 B DKK

	Revenue	EBIT	Net Income
2004	29.03 B DKK	6.98 B DKK	5.01 B DKK
2005	33.76 B DKK	8.09 B DKK	5.86 B DKK
2006	38.74 B DKK	9.12 B DKK	6.45 B DKK
2007	41.83 B DKK	8.94 B DKK	8.52 B DKK
2008	45.55 B DKK	12.37 B DKK	9.65 B DKK
2009	51.08 B DKK	14.93 B DKK	10.77 B DKK
2010	60.78 B DKK	18.89 B DKK	14.4 B DKK
2011	66.35 B DKK	22.37 B DKK	17.1 B DKK
2012	78.03 B DKK	29.47 B DKK	21.43 B DKK
2013	83.57 B DKK	31.64 B DKK	25.18 B DKK
2014	88.81 B DKK	35.13 B DKK	26.48 B DKK
2015	107.93 B DKK	46.96 B DKK	34.86 B DKK
2016	111.78 B DKK	48.97 B DKK	37.93 B DKK
2017	111.7 B DKK	49.28 B DKK	38.13 B DKK
2018	111.83 B DKK	47.24 B DKK	38.63 B DKK
2019	122.02 B DKK	53.68 B DKK	38.95 B DKK
2020	126.95 B DKK	54.6 B DKK	42.14 B DKK
2021	140.8 B DKK	59.36 B DKK	47.76 B DKK
2022	176.95 B DKK	75.67 B DKK	55.53 B DKK
2023	232.26 B DKK	104.7 B DKK	83.68 B DKK
2024e	293.68 B DKK	133.14 B DKK	79.13 B DKK
2025e	354.82 B DKK	164.86 B DKK	96.98 B DKK
2026e	411.2 B DKK	196.99 B DKK	115.15 B DKK
2027e	441.1 B DKK	204.12 B DKK	121.39 B DKK
2028e	484.37 B DKK	228.14 B DKK	134.45 B DKK
2029e	550.96 B DKK	0 DKK	153.28 B DKK

Novo Nordisk A/S Gross margin	Novo Nordisk A/S Profit margin	Novo Nordisk A/S EBIT margin	Novo Nordisk A/S Profit margin
2029e	84.6 %	0 %	27.82 %
2028e	84.6 %	47.1 %	27.76 %
2027e	84.6 %	46.28 %	27.52 %
2026e	84.6 %	47.91 %	28 %
2025e	84.6 %	46.46 %	27.33 %
2024e	84.6 %	45.34 %	26.95 %
2023	84.6 %	45.08 %	36.03 %
2022	83.92 %	42.76 %	31.38 %
2021	83.2 %	42.16 %	33.92 %
2020	83.51 %	43.01 %	33.19 %
2019	83.97 %	43.99 %	31.92 %
2018	84.25 %	42.24 %	34.54 %
2017	84.21 %	44.12 %	34.14 %
2016	84.63 %	43.81 %	33.93 %
2015	85 %	43.51 %	32.3 %
2014	83.6 %	39.56 %	29.82 %
2013	83.08 %	37.86 %	30.13 %
2012	82.74 %	37.77 %	27.47 %
2011	81.03 %	33.72 %	25.77 %
2010	80.78 %	31.08 %	23.7 %
2009	79.56 %	29.24 %	21.08 %
2008	77.81 %	27.16 %	21.17 %
2007	76.59 %	21.38 %	20.37 %
2006	75.26 %	23.54 %	16.65 %
2005	72.82 %	23.96 %	17.37 %
2004	72.27 %	24.04 %	17.27 %

	Gross margin	EBIT margin	Profit margin
2004	72.27 %	24.04 %	17.27 %
2005	72.82 %	23.96 %	17.37 %
2006	75.26 %	23.54 %	16.65 %
2007	76.59 %	21.38 %	20.37 %
2008	77.81 %	27.16 %	21.17 %
2009	79.56 %	29.24 %	21.08 %
2010	80.78 %	31.08 %	23.7 %
2011	81.03 %	33.72 %	25.77 %
2012	82.74 %	37.77 %	27.47 %
2013	83.08 %	37.86 %	30.13 %
2014	83.6 %	39.56 %	29.82 %
2015	85 %	43.51 %	32.3 %
2016	84.63 %	43.81 %	33.93 %
2017	84.21 %	44.12 %	34.14 %
2018	84.25 %	42.24 %	34.54 %
2019	83.97 %	43.99 %	31.92 %
2020	83.51 %	43.01 %	33.19 %
2021	83.2 %	42.16 %	33.92 %
2022	83.92 %	42.76 %	31.38 %
2023	84.6 %	45.08 %	36.03 %
2024e	84.6 %	45.34 %	26.95 %
2025e	84.6 %	46.46 %	27.33 %
2026e	84.6 %	47.91 %	28 %
2027e	84.6 %	46.28 %	27.52 %
2028e	84.6 %	47.1 %	27.76 %
2029e	84.6 %	0 %	27.82 %

Date	Novo Nordisk A/S Sales per Share	Novo Nordisk A/S EBIT per share	Novo Nordisk A/S Earnings per Share
2029e	165.04 DKK	0 DKK	45.91 DKK
2028e	145.09 DKK	0 DKK	40.27 DKK
2027e	132.13 DKK	0 DKK	36.36 DKK
2026e	123.17 DKK	0 DKK	34.49 DKK
2025e	106.28 DKK	0 DKK	29.05 DKK
2024e	87.97 DKK	0 DKK	23.7 DKK
2023	51.67 DKK	23.29 DKK	18.62 DKK
2022	38.94 DKK	16.65 DKK	12.22 DKK
2021	30.57 DKK	12.89 DKK	10.37 DKK
2020	27.13 DKK	11.67 DKK	9 DKK
2019	25.65 DKK	11.29 DKK	8.19 DKK
2018	23.06 DKK	9.74 DKK	7.97 DKK
2017	22.54 DKK	9.94 DKK	7.69 DKK
2016	22.05 DKK	9.66 DKK	7.48 DKK
2015	20.94 DKK	9.11 DKK	6.76 DKK
2014	16.88 DKK	6.68 DKK	5.03 DKK
2013	15.51 DKK	5.87 DKK	4.67 DKK
2012	14.14 DKK	5.34 DKK	3.88 DKK
2011	11.64 DKK	3.92 DKK	3 DKK
2010	10.38 DKK	3.23 DKK	2.46 DKK
2009	8.45 DKK	2.47 DKK	1.78 DKK
2008	7.34 DKK	1.99 DKK	1.55 DKK
2007	6.57 DKK	1.41 DKK	1.34 DKK
2006	6 DKK	1.41 DKK	1 DKK
2005	5.13 DKK	1.23 DKK	0.89 DKK
2004	4.29 DKK	1.03 DKK	0.74 DKK

	Sales per Share	EBIT per share	Earnings per Share
2004	4.29 DKK	1.03 DKK	0.74 DKK
2005	5.13 DKK	1.23 DKK	0.89 DKK
2006	6 DKK	1.41 DKK	1 DKK
2007	6.57 DKK	1.41 DKK	1.34 DKK
2008	7.34 DKK	1.99 DKK	1.55 DKK
2009	8.45 DKK	2.47 DKK	1.78 DKK
2010	10.38 DKK	3.23 DKK	2.46 DKK
2011	11.64 DKK	3.92 DKK	3 DKK
2012	14.14 DKK	5.34 DKK	3.88 DKK
2013	15.51 DKK	5.87 DKK	4.67 DKK
2014	16.88 DKK	6.68 DKK	5.03 DKK
2015	20.94 DKK	9.11 DKK	6.76 DKK
2016	22.05 DKK	9.66 DKK	7.48 DKK
2017	22.54 DKK	9.94 DKK	7.69 DKK
2018	23.06 DKK	9.74 DKK	7.97 DKK
2019	25.65 DKK	11.29 DKK	8.19 DKK
2020	27.13 DKK	11.67 DKK	9 DKK
2021	30.57 DKK	12.89 DKK	10.37 DKK
2022	38.94 DKK	16.65 DKK	12.22 DKK
2023	51.67 DKK	23.29 DKK	18.62 DKK
2024e	87.97 DKK	0 DKK	23.7 DKK
2025e	106.28 DKK	0 DKK	29.05 DKK
2026e	123.17 DKK	0 DKK	34.49 DKK
2027e	132.13 DKK	0 DKK	36.36 DKK
2028e	145.09 DKK	0 DKK	40.27 DKK
2029e	165.04 DKK	0 DKK	45.91 DKK

	Number of stocks
2004	6.76 B Aktien
2005	6.58 B Aktien
2006	6.45 B Aktien
2007	6.36 B Aktien
2008	6.21 B Aktien
2009	6.04 B Aktien
2010	5.86 B Aktien
2011	5.7 B Aktien
2012	5.52 B Aktien
2013	5.39 B Aktien
2014	5.26 B Aktien
2015	5.16 B Aktien
2016	5.07 B Aktien
2017	4.96 B Aktien
2018	4.85 B Aktien
2019	4.76 B Aktien
2020	4.68 B Aktien
2021	4.61 B Aktien
2022	4.54 B Aktien
2023	4.49 B Aktien
2024e	4.49 B Aktien
2025e	4.49 B Aktien
2026e	4.49 B Aktien
2027e	4.49 B Aktien
2028e	4.49 B Aktien
2029e	4.49 B Aktien

Date	Novo Nordisk A/S Dividend
2029e	14.94 DKK
2028e	14.94 DKK
2027e	14.95 DKK
2026e	14.93 DKK
2025e	14.94 DKK
2024e	14.97 DKK
2023	14.15 DKK
2022	11.15 DKK
2021	9.35 DKK
2020	8.6 DKK
2019	8.15 DKK
2018	7.85 DKK
2017	7.6 DKK
2016	9.4 DKK
2015	5 DKK
2014	4.5 DKK
2013	3.6 DKK
2012	2.8 DKK
2011	2 DKK
2010	1.5 DKK
2009	1.2 DKK
2008	0.9 DKK
2007	0.7 DKK
2006	0.6 DKK
2005	0.48 DKK
2004	0.44 DKK

	Dividend	Dividend (Estimate)
2004	0.44 DKK	0 DKK
2005	0.48 DKK	0 DKK
2006	0.6 DKK	0 DKK
2007	0.7 DKK	0 DKK
2008	0.9 DKK	0 DKK
2009	1.2 DKK	0 DKK
2010	1.5 DKK	0 DKK
2011	2 DKK	0 DKK
2012	2.8 DKK	0 DKK
2013	3.6 DKK	0 DKK
2014	4.5 DKK	0 DKK
2015	5 DKK	0 DKK
2016	9.4 DKK	0 DKK
2017	7.6 DKK	0 DKK
2018	7.85 DKK	0 DKK
2019	8.15 DKK	0 DKK
2020	8.6 DKK	0 DKK
2021	9.35 DKK	0 DKK
2022	11.15 DKK	0 DKK
2023	14.15 DKK	0 DKK
2024e	0 DKK	14.97 DKK
2025e	0 DKK	14.94 DKK
2026e	0 DKK	14.93 DKK
2027e	0 DKK	14.95 DKK
2028e	0 DKK	14.94 DKK
2029e	0 DKK	14.94 DKK

Date	Novo Nordisk A/S Payout ratio
2029e	91.62 %
2028e	91.62 %
2027e	91.52 %
2026e	91.72 %
2025e	91.6 %
2024e	91.24 %
2023	92.32 %
2022	91.24 %
2021	90.16 %
2020	95.56 %
2019	99.51 %
2018	98.49 %
2017	98.83 %
2016	125.67 %
2015	73.96 %
2014	89.46 %
2013	77.09 %
2012	72.16 %
2011	66.67 %
2010	60.98 %
2009	67.42 %
2008	58.06 %
2007	52.24 %
2006	60 %
2005	53.93 %
2004	59.46 %

	Payout ratio
2004	59.46 %
2005	53.93 %
2006	60 %
2007	52.24 %
2008	58.06 %
2009	67.42 %
2010	60.98 %
2011	66.67 %
2012	72.16 %
2013	77.09 %
2014	89.46 %
2015	73.96 %
2016	125.67 %
2017	98.83 %
2018	98.49 %
2019	99.51 %
2020	95.56 %
2021	90.16 %
2022	91.24 %
2023	92.32 %
2024e	91.24 %
2025e	91.6 %
2026e	91.72 %
2027e	91.52 %
2028e	91.62 %
2029e	91.62 %

Date	EPS Estimate	EPS Actual	Quarterly report
3/31/2024	5.29 DKK	5.68 DKK (7.46 %)	2024 Q1
12/31/2023	4.58 DKK	4.91 DKK (7.31 %)	2023 Q4
9/30/2023	4.68 DKK	5 DKK (6.79 %)	2023 Q3
6/30/2023	4.62 DKK	4.32 DKK (-6.63 %)	2023 Q2
3/31/2023	4.3 DKK	4.39 DKK (2.11 %)	2023 Q1
12/31/2022	2.93 DKK	3.01 DKK (2.85 %)	2022 Q4
9/30/2022	3.13 DKK	3.17 DKK (1.32 %)	2022 Q3
6/30/2022	3.02 DKK	2.93 DKK (-3.12 %)	2022 Q2
3/31/2022	2.88 DKK	3.11 DKK (8.13 %)	2022 Q1
12/31/2021	4.75 DKK	4.76 DKK (0.18 %)	2021 Q4
9/30/2021	5.05 DKK	5.27 DKK (4.34 %)	2021 Q3
6/30/2021	4.82 DKK	5.26 DKK (9.15 %)	2021 Q2
3/31/2021	5.13 DKK	5.45 DKK (6.25 %)	2021 Q1
12/31/2020	3.94 DKK	4.01 DKK (1.74 %)	2020 Q4
9/30/2020	4.5 DKK	4.42 DKK (-1.76 %)	2020 Q3
6/30/2020	4.37 DKK	4.53 DKK (3.69 %)	2020 Q2
3/31/2020	4.73 DKK	5.05 DKK (6.87 %)	2020 Q1
12/31/2019	3.85 DKK	3.7 DKK (-3.82 %)	2019 Q4
9/30/2019	4.16 DKK	4.29 DKK (3.13 %)	2019 Q3
6/30/2019	4.08 DKK	4.03 DKK (-1.23 %)	2019 Q2
3/31/2019	4.13 DKK	4.36 DKK (5.62 %)	2019 Q1
12/31/2018	3.75 DKK	3.53 DKK (-5.88 %)	2018 Q4
9/30/2018	3.95 DKK	3.74 DKK (-5.33 %)	2018 Q3
6/30/2018	4.2 DKK	4.26 DKK (1.46 %)	2018 Q2
3/31/2018	4.14 DKK	4.4 DKK (6.36 %)	2018 Q1
12/31/2017	3.54 DKK	3.36 DKK (-5.2 %)	2017 Q4
9/30/2017	3.84 DKK	3.96 DKK (3.1 %)	2017 Q3
6/30/2017	3.9 DKK	4.01 DKK (2.7 %)	2017 Q2
3/31/2017	3.68 DKK	4.06 DKK (10.38 %)	2017 Q1
12/31/2016	3.56 DKK	3.46 DKK (-2.91 %)	2016 Q4
9/30/2016	3.8 DKK	3.87 DKK (1.92 %)	2016 Q3
6/30/2016	3.94 DKK	3.92 DKK (-0.49 %)	2016 Q2
3/31/2016	3.65 DKK	3.71 DKK (1.58 %)	2016 Q1
12/31/2015	3.4 DKK	3.24 DKK (-4.63 %)	2015 Q4
9/30/2015	3.33 DKK	3.26 DKK (-1.98 %)	2015 Q3
6/30/2015	3.23 DKK	3.23 DKK (0.13 %)	2015 Q2
3/31/2015	3.35 DKK	3.79 DKK (13.24 %)	2015 Q1
12/31/2014	2.5 DKK	2.51 DKK (0.4 %)	2014 Q4
9/30/2014	2.63 DKK	2.47 DKK (-6.06 %)	2014 Q3
6/30/2014	2.61 DKK	2.66 DKK (1.83 %)	2014 Q2
3/31/2014	2.46 DKK	2.43 DKK (-1.15 %)	2014 Q1
12/31/2013	2.37 DKK	2.27 DKK (-4.09 %)	2013 Q4
9/30/2013	2.47 DKK	2.39 DKK (-3 %)	2013 Q3
6/30/2013	2.44 DKK	2.49 DKK (2.04 %)	2013 Q2
3/31/2013	2.16 DKK	2.2 DKK (1.57 %)	2013 Q1
12/31/2012	1.95 DKK	2.11 DKK (7.96 %)	2012 Q4
9/30/2012	1.91 DKK	2.07 DKK (8.25 %)	2012 Q3
6/30/2012	1.72 DKK	1.93 DKK (12.44 %)	2012 Q2
3/31/2012	1.72 DKK	1.66 DKK (-3.24 %)	2012 Q1
12/31/2011	1.48 DKK	1.67 DKK (12.6 %)	2011 Q4
9/30/2011	1.5 DKK	1.48 DKK (-1.66 %)	2011 Q3
6/30/2011	1.51 DKK	1.44 DKK (-4.47 %)	2011 Q2
3/31/2011	1.39 DKK	1.41 DKK (1.58 %)	2011 Q1
12/31/2010	1.44 DKK	1.36 DKK (-5.57 %)	2010 Q4
9/30/2010	1.14 DKK	1.23 DKK (7.44 %)	2010 Q3
6/30/2010	1.15 DKK	1.2 DKK (4.75 %)	2010 Q2
3/31/2010	1.05 DKK	1.12 DKK (6.59 %)	2010 Q1
12/31/2009	0.82 DKK	0.78 DKK (-4.29 %)	2009 Q4
9/30/2009	0.88 DKK	0.92 DKK (4.35 %)	2009 Q3
6/30/2009	0.85 DKK	0.99 DKK (17.26 %)	2009 Q2
3/31/2009	0.81 DKK	0.89 DKK (10.17 %)	2009 Q1
12/31/2008	0.71 DKK	0.76 DKK (6.92 %)	2008 Q4
9/30/2008	0.77 DKK	0.87 DKK (12.83 %)	2008 Q3
6/30/2008	0.75 DKK	0.8 DKK (6.28 %)	2008 Q2
3/31/2008	0.69 DKK	0.7 DKK (2.39 %)	2008 Q1
12/31/2007	0.66 DKK	0.31 DKK (-52.39 %)	2007 Q4
9/30/2007	0.69 DKK	0.69 DKK (0.51 %)	2007 Q3
6/30/2007	0.62 DKK	0.72 DKK (15.87 %)	2007 Q2
3/31/2007	0.73 DKK	0.54 DKK (-26.66 %)	2007 Q1
12/31/2006	0.51 DKK	0.54 DKK (5.84 %)	2006 Q4
9/30/2006	0.53 DKK	0.55 DKK (3.8 %)	2006 Q3
6/30/2006	0.48 DKK	0.54 DKK (12.85 %)	2006 Q2
3/31/2006	0.38 DKK	0.37 DKK (-3.07 %)	2006 Q1
12/31/2005	0.37 DKK	0.37 DKK (0 %)	2005 Q4
9/30/2005	0.43 DKK	0.53 DKK (24.68 %)	2005 Q3
6/30/2005	0.4 DKK	0.51 DKK (27.88 %)	2005 Q2
3/31/2005	0.41 DKK	0.37 DKK (-9.4 %)	2005 Q1
12/31/2004	0.39 DKK	0.44 DKK (11.71 %)	2004 Q4
9/30/2004	0.34 DKK	0.36 DKK (6.06 %)	2004 Q3
6/30/2004	0.34 DKK	0.38 DKK (11.11 %)	2004 Q2
3/31/2004	0.3 DKK	0.31 DKK (2.64 %)	2004 Q1
9/30/2003	0.29 DKK	0.33 DKK (14.13 %)	2003 Q3

%	Name	Stocks	Change	Date
6.12 %	Novo A/S	204,208,000	-16,830,000	1/31/2023
3.53 %	Capital Research Global Investors	117,721,080	-8,123,700	3/31/2024
2.77 %	The Vanguard Group, Inc.	92,360,353	-2,007,330	3/31/2024
2.53 %	Norges Bank Investment Management (NBIM)	84,496,890	-1,305,158	12/31/2023
2.00 %	Capital World Investors	66,733,131	-10,807,918	3/31/2024
1.69 %	BlackRock Institutional Trust Company, N.A.	56,305,096	527,773	3/31/2024
1.13 %	Fundsmith LLP	37,791,152	3,081,000	11/30/2023
1.05 %	BlackRock Investment Management (UK) Ltd.	34,917,565	-307,935	3/31/2024
0.80 %	Fidelity Management & Research Company LLC	26,802,024	1,275,085	2/29/2024
0.75 %	GQG Partners, LLC	25,198,093	-492,369	2/29/2024
0.72 %	Nuveen LLC	24,063,762	-236,965	3/31/2024
0.70 %	BlackRock Advisors (UK) Limited	23,311,384	126,407	3/31/2024
0.66 %	Geode Capital Management, L.L.C.	22,041,454	2,806	3/31/2024
0.59 %	Handelsbanken Kapitalförvaltning AB	19,648,398	-702,910	3/31/2024
0.42 %	Amundi Asset Management, SAS	13,983,886	-4,512,317	3/31/2024
0.40 %	WCM Investment Management	13,191,017	-21,410	2/29/2024
0.38 %	Allianz Global Investors GmbH	12,798,506	559,414	3/31/2024
0.38 %	Invesco Advisers, Inc.	12,561,353	206,492	2/29/2024
0.35 %	MFS Investment Management	11,636,384	-52,480	3/31/2024
0.34 %	JPMorgan Asset Management U.K. Limited	11,283,871	-168,583	3/31/2024
0.32 %	Janus Henderson Investors	10,578,561	0	3/31/2024
0.30 %	BlackRock Investment Management, LLC	10,061,887	-6,542	2/29/2024
0.28 %	Comgest S.A.	9,301,582	0	12/31/2023
0.27 %	RBC Global Asset Management (UK) Limited	8,888,270	6,725	2/29/2024
0.26 %	Swedbank Robur Fonder AB	8,613,983	34,754	2/29/2024
0.26 %	Mawer Investment Management Ltd.	8,597,631	-2,139	1/31/2024
0.25 %	Deka Investment GmbH	8,363,748	-49,193	3/31/2024
0.25 %	CPP Investment Board	8,322,000	2,808,000	3/31/2023
0.25 %	Nordea Investment Management AB (Denmark)	8,301,927	33,256	2/29/2024
0.25 %	Fidelity International	8,190,253	26,303	2/29/2024
0.25 %	Charles Schwab Investment Management, Inc.	8,182,450	-25,443	3/31/2024
0.24 %	Walter Scott & Partners Ltd.	7,912,208	0	3/31/2024
0.23 %	APG Asset Management N.V.	7,842,507	-130,259	9/30/2023
0.23 %	FMR Investment Management (U.K.) Limited	7,755,087	5,039	2/29/2024
0.23 %	AllianceBernstein L.P.	7,620,500	-224,086	2/29/2024
0.22 %	JP Morgan Asset Management	7,457,170	123,779	3/31/2024
0.22 %	DWS Investments UK Limited	7,408,490	-20,707	3/31/2024
0.22 %	DWS Investment GmbH	7,333,579	22,300	3/31/2024
0.22 %	Wellington Management Company, LLP	7,265,912	143,359	2/29/2024
0.21 %	Dimensional Fund Advisors, L.P.	7,058,771	59,178	3/31/2024
0.19 %	SEB Investment Management AB	6,332,270	-120,355	2/29/2024
0.18 %	Caisse de Depot et Placement du Quebec	6,050,582	-2,091,726	12/31/2022
0.18 %	Jennison Associates LLC	6,033,021	11,079	3/31/2024
0.17 %	Schroder Investment Management Ltd. (SIM)	5,810,150	-6,656	3/31/2024
0.17 %	Aviva Investors Global Services Limited	5,516,310	584	3/31/2024
0.16 %	Union Investment Privatfonds GmbH	5,385,818	-433,173	12/31/2023
0.16 %	T. Rowe Price Associates, Inc.	5,327,319	479,248	3/31/2024
0.16 %	State Street Global Advisors (US)	5,245,737	-1,216	3/31/2024
0.15 %	Baillie Gifford & Co.	5,030,875	-133,766	2/29/2024
0.15 %	Nordea Funds Oy	4,847,130	-120,381	2/29/2024
0.14 %	Carmignac Gestion	4,763,066	-4,000	2/29/2024
0.14 %	California State Teachers Retirement System	4,618,858	-448,976	6/30/2023
0.14 %	Artisan Partners Limited Partnership	4,579,208	-34,439	3/31/2024
0.14 %	Florida State Board of Administration	4,571,846	-71,202	9/30/2022
0.14 %	Eleva Capital SAS	4,551,394	149,892	12/31/2023
0.13 %	Morgan Stanley Investment Management Inc. (US)	4,471,008	859	3/31/2024
0.13 %	PensionDanmark A/S	4,381,840	55,666	8/31/2023
0.13 %	Royal London Asset Management Ltd.	4,267,230	-23,038	12/31/2023
0.12 %	HSBC Global Asset Management (UK) Limited	4,129,233	92,072	2/29/2024
0.12 %	Legal & General Investment Management Ltd.	4,120,556	-35,738	3/31/2024
0.12 %	Danske Bank Asset Management	4,019,848	-3,176	3/31/2024
0.12 %	State Street Global Advisors (UK) Ltd.	3,960,916	-14,952	3/31/2024
0.11 %	Robeco Institutional Asset Management B.V.	3,836,944	279,526	2/29/2024
0.11 %	PineStone Asset Management Inc.	3,805,828	3,984	2/29/2024
0.11 %	UBS Asset Management (UK) Ltd.	3,774,669	6,653	3/31/2024
0.11 %	BlackRock Asset Management Deutschland AG	3,724,144	-11,943	3/31/2024
0.11 %	Nykredit Bank AS	3,723,275	-1,312	3/31/2024
0.11 %	Columbia Threadneedle Investments (UK)	3,515,207	-8,819	2/29/2024
0.11 %	Jupiter Asset Management Ltd.	3,506,916	0	2/29/2024
0.10 %	Eurizon Capital SGR S.p.A.	3,456,933	-200,412	2/29/2024
0.10 %	American Century Investment Management, Inc.	3,434,376	-4,985	3/31/2024
0.10 %	DNCA Investments	3,223,563	-9,884	2/29/2024
0.10 %	TD Asset Management Inc.	3,217,892	42,653	3/31/2024
0.09 %	Cardano Asset Management NV	3,087,676	-43,743	2/29/2024
0.09 %	C WorldWide Asset Management Fondsmaeglerselskab A/S	2,997,884	-427,268	3/31/2024
0.09 %	Pictet Asset Management Ltd.	2,974,942	8,625	2/29/2024
0.09 %	Lazard Asset Management, L.L.C.	2,923,976	-3,054	3/31/2024
0.09 %	ClearBridge Investments, LLC	2,858,951	-82,693	2/29/2024
0.08 %	Northern Trust Global Investments Limited	2,823,007	65,292	12/31/2023
0.08 %	DNB Asset Management AS	2,812,114	380,304	2/29/2024
0.08 %	Vanguard Global Advisers LLC	2,620,866	77,536	3/31/2024
0.08 %	Goldman Sachs Asset Management B.V.	2,573,261	-12,359	1/31/2024
0.08 %	OP Varainhoito Oy	2,561,996	100,442	2/29/2024
0.08 %	KLP Fondsforvaltning AS	2,541,166	25,801	2/29/2024
0.08 %	BlackRock Financial Management, Inc.	2,507,717	-4,546	2/29/2024
0.07 %	DWS International GmbH	2,499,646	28,045	3/31/2024
0.07 %	Mackenzie Financial Corporation	2,492,807	-31,063	3/31/2024
0.07 %	Mirova US LLC	2,468,236	-55,276	2/29/2024
0.07 %	State Street Global Advisors Ireland Limited	2,411,352	-485,749	3/31/2024
0.07 %	Credit Suisse Funds AG	2,386,715	-19,286	3/31/2024
0.07 %	PGGM Vermogensbeheer B.V.	2,361,692	262,114	7/31/2023
0.07 %	Zürcher Kantonalbank (Asset Management)	2,295,306	-27,855	3/31/2024
0.07 %	Guinness Atkinson Asset Management Inc.	2,268,029	0	3/31/2024
0.07 %	Candriam Luxembourg S.A.	2,175,130	69,697	2/29/2024
0.06 %	J O Hambro Capital Management Limited	2,151,521	-85,865	2/29/2024
0.06 %	M&G Investment Management Ltd.	2,110,257	22,768	1/31/2024
0.06 %	Capfi Delen Asset Management	2,050,225	1,001	12/31/2023
0.06 %	Mellon Investments Corporation	2,019,575	-5,783	3/31/2024
0.06 %	Schroder Investment Management North America Inc.	1,994,472	14,412	2/29/2024
0.06 %	Vanguard Investments Australia Ltd.	1,990,108	582	2/29/2024

What values and corporate philosophy does Novo Nordisk A/S represent?

Novo Nordisk A/S is a leading pharmaceutical company that embodies values of integrity, innovation, and accountability. With a strong focus on improving the lives of patients, Novo Nordisk is committed to sustainable healthcare and pioneering treatments for diabetes and other chronic conditions. The company's corporate philosophy revolves around patient-centricity, scientific excellence, and ethical business practices. Novo Nordisk aims to create long-term value for stakeholders while ensuring accessibility and affordability of its life-saving therapies. Through extensive research and development, Novo Nordisk continuously strives to deliver innovative solutions that positively impact global health.

In which countries and regions is Novo Nordisk A/S primarily present?

Novo Nordisk A/S is primarily present in countries and regions worldwide. As a leading global pharmaceutical company specializing in diabetes care, Novo Nordisk operates in more than 170 countries. Its presence extends across North America, Europe, Asia, Africa, and South America. With its headquarters situated in Denmark, Novo Nordisk has a strong presence in its home country. The company's expansive reach allows it to provide innovative diabetes treatments and other healthcare solutions to a diverse range of individuals and communities globally.

What significant milestones has the company Novo Nordisk A/S achieved?

Novo Nordisk A/S, a leading global pharmaceutical company, has achieved significant milestones throughout its history. Notably, Novo Nordisk introduced the world's first insulin for diabetes treatment in 1923. Over the years, the company has consistently pioneered innovative medicines and devices for diabetes and other serious chronic conditions such as obesity, hemophilia, and growth disorders. Novo Nordisk's commitment to research and development has led to numerous breakthroughs in insulin therapies, including the launch of long-acting insulin analogs and the first concentrated insulin for diabetes patients. Furthermore, the company has expanded its global presence, ensuring access to life-saving medications in more than 170 countries. Novo Nordisk's relentless pursuit of improving patient care has established it as a trusted leader in the healthcare industry.

What is the history and background of the company Novo Nordisk A/S?

Novo Nordisk A/S is a renowned pharmaceutical company founded in 1923 in Denmark. With a strong commitment to improving the lives of people with diabetes and other chronic diseases, Novo Nordisk has become a global leader in the field. Over the years, the company has built a rich history of innovation, developing groundbreaking insulin and other therapeutic solutions. Novo Nordisk has expanded its portfolio to include products for obesity, rare bleeding disorders, and growth hormone deficiencies. With its dedication to research and development, Novo Nordisk continues to strive for better treatment options, making a significant impact on patients worldwide.

Who are the main competitors of Novo Nordisk A/S in the market?

The main competitors of Novo Nordisk A/S in the market are Eli Lilly and Company, Sanofi S.A., and Johnson & Johnson.

In which industries is Novo Nordisk A/S primarily active?

Novo Nordisk A/S is primarily active in the pharmaceutical industry, specifically focused on diabetes care. With a strong emphasis on research, development, and production of diabetes medication and innovative treatment solutions, Novo Nordisk leads the way in delivering effective therapies for managing diabetes. The company also engages in the production of other biopharmaceuticals, such as hemophilia treatments, growth disorders, and obesity therapies. Novo Nordisk excels in providing comprehensive healthcare solutions within the field of endocrinology, catering to the needs of patients worldwide.

What is the business model of Novo Nordisk A/S?

Novo Nordisk A/S is a renowned global pharmaceutical company specializing in the production and distribution of diabetes care products. The business model of Novo Nordisk is centered around developing innovative and effective treatments for diabetes and other serious chronic diseases. With a strong focus on research and development, Novo Nordisk aims to provide accessible and high-quality healthcare solutions to improve the lives of people worldwide. Through strategic partnerships, extensive market presence, and continuous product advancements, Novo Nordisk strives to address the growing global health challenges while maintaining sustainable business growth.

What is the P/E ratio of Novo Nordisk A/S 2024?

The Novo Nordisk A/S P/E ratio is 51.26.

What is the P/S ratio of Novo Nordisk A/S 2024?

The Novo Nordisk A/S P/S ratio is 13.81.

What is the AlleAktien quality score of Novo Nordisk A/S?

The AlleAktien quality score for Novo Nordisk A/S is 10/10.

What is the revenue of Novo Nordisk A/S 2024?

The expected Novo Nordisk A/S revenue is 293.68 B DKK.

How high is the profit of Novo Nordisk A/S 2024?

The expected Novo Nordisk A/S profit is 79.13 B DKK.

What is the business model of Novo Nordisk A/S

Novo Nordisk A/S is a Danish company specializing in the development and production of diabetes medications. It operates globally and offers products and services in over 170 countries. The company has three business areas: Diabetes and Obesity, Biopharmaceuticals, and Hemophilia. The Diabetes and Obesity business area is the core of its business model, offering insulin products, GLP-1 analogs, and other medications for diabetes and obesity treatment. Novo Nordisk also provides digital solutions for patient management and self-care. The Biopharmaceuticals business area focuses on developing medications for inflammatory diseases, metabolic disorders, and other critical conditions. The Hemophilia business area includes factor replacement therapies for the treatment of hemophilia and other bleeding disorders. Novo Nordisk complements its business model with research and development initiatives to optimize existing products and develop new ones. The company has global research centers and production sites in Denmark, China, Brazil, and the United States. It also engages in partnerships and collaborations to accelerate the development and production of diabetes products and other medications. Overall, Novo Nordisk's business model offers an integrated solution to improve the health and well-being of diabetes patients worldwide, combining innovative technology and traditional treatment approaches to meet the needs of patients, doctors, and healthcare systems.

What is the Novo Nordisk A/S dividend?

Novo Nordisk A/S pays a dividend of 11.15 DKK distributed over 2 payouts per year.

How often does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays out a dividend 2 times a year.

What is the Novo Nordisk A/S ISIN?

The ISIN of Novo Nordisk A/S is DK0060534915.

What is the Novo Nordisk A/S WKN?

The WKN of Novo Nordisk A/S is A1XA8R.

What is the Novo Nordisk A/S ticker?

The ticker of Novo Nordisk A/S is NOVO B.CO.

How much dividend does Novo Nordisk A/S pay?

Over the past 12 months, Novo Nordisk A/S paid a dividend of 14.15 DKK . This corresponds to a dividend yield of about 1.57 %. For the coming 12 months, Novo Nordisk A/S is expected to pay a dividend of 14.94 DKK.

What is the dividend yield of Novo Nordisk A/S?

The current dividend yield of Novo Nordisk A/S is 1.57 %.

When does Novo Nordisk A/S pay dividends?

Novo Nordisk A/S pays a quarterly dividend. This is distributed in the months of September, April, September, April.

How secure is the dividend of Novo Nordisk A/S?

Novo Nordisk A/S paid dividends every year for the past 26 years.

What is the dividend of Novo Nordisk A/S?

For the upcoming 12 months, dividends amounting to 14.94 DKK are expected. This corresponds to a dividend yield of 1.69 %.

In which sector is Novo Nordisk A/S located?

Novo Nordisk A/S is assigned to the 'Health' sector.

Wann musste ich die Aktien von Novo Nordisk A/S kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Novo Nordisk A/S from 3/26/2024 amounting to 6.4 DKK, you needed to have the stock in your portfolio before the ex-date on 3/22/2024.

When did Novo Nordisk A/S pay the last dividend?

The last dividend was paid out on 3/26/2024.

What was the dividend of Novo Nordisk A/S in the year 2023?

In the year 2023, Novo Nordisk A/S distributed 11.15 DKK as dividends.

In which currency does Novo Nordisk A/S pay out the dividend?

The dividends of Novo Nordisk A/S are distributed in DKK.

1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
1.43	1.43	1.56	1.76	2.1	2.02	2	3.09	3.87	4.12	4.83	5.01	5.86	6.45	8.52	9.65	10.77	14.4	17.1	21.43	25.18	26.48	34.86	37.93	38.13	38.63	38.95	42.14	47.76	55.53	83.68
0.8	1.06	1.14	1.22	1.31	0.99	0.94	1.04	1.08	1.29	1.58	1.89	1.93	2.14	3.01	2.44	2.55	2.47	2.74	2.69	2.8	3.44	2.96	3.19	3.18	3.93	5.66	5.75	6.03	7.36	9.41
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-2	-1,945	-4,631	0
-539	-131	-950	-1,837	-1,241	-1,744	-1,412	-676	-3,076	-2,991	-3,072	-2,650	-2,605	-4,454	-3,666	-2,826	-2,036	-3,216	-4,875	-10,458	-10,104	-9,566	-11,537	-6,559	-12,721	-12,610	-14,464	-14,781	-23,114	-19,847	-37,561
0.22	-0.19	0.78	0.91	0.96	1.19	1.3	1.81	2.45	2.45	2.81	3.33	3.52	3.6	2.12	3.6	4.1	6.03	6.42	8.55	8.06	11.34	12.01	13.76	12.58	15.09	16.63	18.84	24.33	35.85	53.37
0	0	315	106	119	120	94	142	0	0	0	0	0	296	324	247	98	252	215	61	39	78	61	66	87	89	204	422	261	272	491
0	0	0.87	1.03	0.79	1.54	1.28	1.74	1.9	2.27	1.8	2.87	2.14	3.51	2.61	3.17	2	3.44	5.39	10.89	9.81	7.91	9.37	2.9	9.1	9.61	10.94	10.11	14.44	14.52	25.9
1.91	2.17	2.53	2.06	3.13	2.45	2.83	5.26	4.32	4.87	6.15	7.59	8.71	7.74	9.99	12.86	15.38	19.68	21.37	22.21	25.94	31.69	38.29	48.31	41.17	45.03	46.78	51.95	55	78.89	108.91
-2,595	-1,907	-1,601	-2,183	-2,707	-1,871	-1,390	-2,429	-4,248	-4,024	-2,498	-3,451	-4,163	-3,317	-2,426	-2,036	-3,065	-3,897	-3,332	-3,622	-3,644	-4,335	-6,406	-8,267	-8,648	-12,410	-11,231	-22,081	-7,385	-14,753	-38,896
-2,595	-1,907	-1,013	-2,127	-2,544	-1,739	-1,294	-2,546	-4,134	-3,285	-3,819	-2,001	-4,911	-2,517	-1,516	-1,382	-3,046	-5,579	-3,459	-4,070	-2,773	-2,064	-6,098	-6,790	-6,571	-12,080	-11,509	-22,436	-31,605	-24,918	-43,892
0	0	0.59	0.06	0.16	0.13	0.1	-0.12	0.11	0.74	-1.32	1.45	-0.75	0.8	0.91	0.65	0.02	-1.68	-0.13	-0.45	0.87	2.27	0.31	1.48	2.08	0.33	-0.28	-0.36	-24.22	-10.17	-5
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0.69	0.89	-1.16	-1.05	0.79	0.64	2.24	0	-0.04	-0.02	0.45	-0.07	-0.03	-0.02	-0.02	-0.15	0	0	-0.51	-0.5	0	0	0	0	0	0.09	-0.74	4.73	15.47	-2.41	-1.47
0	0	0	0	0	-1,940	-1,438	-1,465	10	-347	-1,604	-1,895	-2,812	-2,790	-4,594	-4,422	-6,395	-8,820	-10,595	-11,896	-13,924	-14,667	-17,196	-15,057	-16,845	-15,567	-15,334	-16,855	-19,447	-24,086	-29,924
536	737	-1,344	-1,239	515	-1,727	244	-2,152	-945	-1,526	-2,394	-3,452	-4,435	-4,758	-6,833	-7,370	-10,045	-13,220	-16,802	-20,140	-23,639	-26,533	-30,101	-38,887	-35,689	-34,521	-35,484	-32,244	-25,493	-51,797	-63,158
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-149	-149	-186	-186	-279	-428	-562	-691	-916	-1,161	-1,243	-1,488	-1,594	-1,945	-2,221	-2,795	-3,650	-4,400	-5,700	-7,742	-9,715	-11,866	-12,905	-23,830	-18,844	-19,048	-19,409	-20,121	-21,517	-25,303	-31,767
-0.15	1	0.07	-1.43	1.22	-1.01	1.79	0.58	-0.79	0.03	-0.08	2.12	-0.48	0.5	1.63	4.11	2.31	0.93	1.1	-2	-0.54	3.16	2.17	2.61	-1.3	-1.53	-0.22	-3.19	-1.51	1.93	1.74
-688	264	931	-126	420	574	1,437	2,829	72	843	3,651	4,138	4,549	4,421	7,561	10,827	12,313	15,782	18,042	18,592	22,298	27,357	31,881	40,047	32,520	32,618	35,551	29,870	47,615	64,134	70,012
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Scope 1 - Direct Emissions	76,000
Scope 2 - Indirect emissions from purchased energy	16,000
Scope 3 - Indirect emissions within the value chain	2,041,000
Total CO₂ emissions	92,000
CO₂ reduction strategy	✅
Coal energy	❌
Nuclear power	❌
Animal experiments	✅
Fur & Leather	—
Pesticides	—
Palm Oil	—
Tobacco	❌
Genetically modified organisms	❌
Climate concept	—
Sustainable forestry	—
Recycling regulations	✅
Environmentally friendly packaging	✅
Hazardous substances	✅
Fuel consumption and efficiency	❌
Water consumption and efficiency	✅

Percentage of female employees	44
Percentage of women in management	—
Percentage of Asian employees	—
Share of Asian management	—
Percentage of Hispanic/Latino employees	—
Hispano/Latino Management share	—
Percentage of Black employees	—
Black Management Share	—
Percentage of white employees	—
White Management Share	—
Adult content	❌
Alcohol	❌
Weapons	—
Firearms	❌
Gambling	❌
Military contracts	❌
Human rights concept	✅
Privacy concept	—
Occupational health and safety	✅
Catholic	✅

Environmental reporting	✅
Stakeholder Engagement	✅
Call Back Policies	❌
Antitrust law	❌

Stock Exchange	Novo Nordisk A/S Ticker
COPENHAGEN	NOVO B.CO
DÜSSELDORF	NOVC.DU
FRANKFURT	NOVC.F
HAMBURG	NOVC.HM
LONDON	0QIU.L
MUNICH	NOVC.MU
SIX	NO.SW
VIENNA	NNOR.VI
XETRA	NOVC.DE

1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
12.16	13.52	13.72	14.87	16.93	13.65	16.42	20.81	23.78	24.87	26.16	29.03	33.76	38.74	41.83	45.55	51.08	60.78	66.35	78.03	83.57	88.81	107.93	111.78	111.7	111.83	122.02	126.95	140.8	176.95	232.26	293.68	354.82	411.2	441.1	484.37	550.96
-	11.19	1.47	8.38	13.84	-19.40	20.34	26.72	14.25	4.58	5.20	10.98	16.29	14.76	7.97	8.90	12.13	18.99	9.16	17.60	7.11	6.26	21.53	3.57	-0.08	0.12	9.11	4.04	10.91	25.68	31.26	26.45	20.82	15.89	7.27	9.81	13.75
64.38	63.84	63.77	66.29	65.92	72.51	74.26	75.76	74.85	73.47	71.68	72.27	72.82	75.26	76.59	77.81	79.56	80.78	81.03	82.74	83.08	83.60	85.00	84.63	84.21	84.25	83.97	83.51	83.20	83.92	84.60	-	-	-	-	-	-
7.83	8.63	8.75	9.86	11.16	9.9	12.2	15.77	17.8	18.27	18.75	20.98	24.58	29.16	32.04	35.44	40.64	49.1	53.76	64.56	69.43	74.24	91.74	94.6	94.06	94.21	102.46	106.01	117.14	148.51	196.5	0	0	0	0	0	0
1.94	2.18	2.26	2.59	3.04	2.93	3.88	4.82	5.61	5.93	6.42	6.98	8.09	9.12	8.94	12.37	14.93	18.89	22.37	29.47	31.64	35.13	46.96	48.97	49.28	47.24	53.68	54.6	59.36	75.67	104.7	133.14	164.86	196.99	204.12	228.14	0
15.93	16.15	16.43	17.42	17.96	21.49	23.61	23.14	23.61	23.84	24.55	24.04	23.96	23.54	21.38	27.16	29.24	31.08	33.72	37.77	37.86	39.56	43.51	43.81	44.12	42.24	43.99	43.01	42.16	42.76	45.08	45.34	46.46	47.91	46.28	47.10	-
1.43	1.43	1.56	1.76	2.1	2.02	2	3.09	3.87	4.12	4.83	5.01	5.86	6.45	8.52	9.65	10.77	14.4	17.1	21.43	25.18	26.48	34.86	37.93	38.13	38.63	38.95	42.14	47.76	55.53	83.68	79.13	96.98	115.15	121.39	134.45	153.28
-	0.42	9.15	12.54	19.22	-3.86	-0.74	54.27	25.20	6.49	17.42	3.72	16.98	10.03	32.08	13.18	11.64	33.76	18.70	25.36	17.51	5.15	31.64	8.79	0.54	1.31	0.84	8.18	13.33	16.27	50.71	-5.44	22.56	18.73	5.42	10.76	14.01
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7.5	7.5	7.5	7.5	7.5	7.43	7.16	7	6.96	6.95	6.83	6.76	6.58	6.45	6.36	6.21	6.04	5.86	5.7	5.52	5.39	5.26	5.16	5.07	4.96	4.85	4.76	4.68	4.61	4.54	4.49	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Own the gold standard ✨ in financial data & analytics fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Price

Price

TickerNOVO B.CO

ISINDK0060534915

WKNA1XA8R

Novo Nordisk A/S Revenue, EBIT, Net Income DK0060534915 · A1XA8R

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Yearly Analysis and Comparisons

Utilizing Expectations for Investment

Investment Insights

Novo Nordisk A/S Revenue, EBIT and net profit per share

Novo Nordisk A/S Income Statement, Balance Sheet, Cash Flow Statement

Keystats

Revenue and Growth

Gross Margin

EBIT and EBIT Margin

Income and Growth

Shares Outstanding

Interpreting Year to Year Comparison

Expectations and Predictions

Balance Sheet

Understanding the Balance Sheet

Assets

Liabilities

Equity

Year-to-Year Analysis

Interpreting the Data

Novo Nordisk A/S stock margins DK0060534915 · A1XA8R

Margin

Understanding Gross Margin

EBIT Margin Analysis

Revenue Margin Insights

Interpreting Expectations

Comparative Analysis

Novo Nordisk A/S Margin History

Novo Nordisk A/S Stock Sales Revenue, EBIT, Earnings per Share DK0060534915 · A1XA8R

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Novo Nordisk A/S Revenue, EBIT and net profit per share

Novo Nordisk A/S business model

Novo Nordisk A/S SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Novo Nordisk A/S historical P/E ratio, EBIT, and P/S ratio.

Novo Nordisk A/S shares outstanding DK0060534915 · A1XA8R

Revenue, EBIT and Earnings per share

Revenue Per Share

EBIT Per Share

Income Per Share

Expected Values

Novo Nordisk A/S Stock splits

Novo Nordisk A/S dividend history and estimates DK0060534915 · A1XA8R

Dividend

Dividend Overview

Interpretation and Use

Investment Strategy

Novo Nordisk A/S Dividend History

Novo Nordisk A/S dividend payout ratio DK0060534915 · A1XA8R

Payout ratio

What is Yearly Payout Ratio?

How to Interpret the Data

Using the Data for Investments

Novo Nordisk A/S Payout Ratio History

Novo Nordisk A/S Earnings Estimates

Novo Nordisk A/S latest earnings and earnings surprises

Eulerpool ESG Scorecard© for the Novo Nordisk A/S stock

Eulerpool World ESG Rating (EESG©)

88/ 100

🌱 Environment

👫 Social

🏛️ Governance

Environment

Social

Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Ticker
NOVO B.CO

ISIN
DK0060534915

WKN
A1XA8R